Skip to main content
logo
Lyell Immunopharma, Inc. (LYEL)
NASDAQ: LYEL · Real-Time Price · USD
14.86
-0.14 (-0.93%)
At close: Nov 6, 2026, 4:00 PM EST
14.82
-0.04 (-0.27%)
After-hours: Nov 6, 2026, 7:46 PM EST

Lyell Immunopharma Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-255.16-274.45-342.99-234.63-183.12-250.22
Depreciation & Amortization
9.0111.5419.6320.2518.0213.62
Loss (Gain) From Sale of Assets
-0.053.341.341.510.11.21
Asset Writedown & Restructuring Costs
66.3367.78138.48---
Loss (Gain) From Sale of Investments
-5.8714.26-1.713.331.1538.35
Stock-Based Compensation
38.9141.8333.1447.0881.9262.2
Other Operating Activities
-5.01-4.43-7.17-4.65-5.624.57
Change in Accounts Payable
1.39-2.34-3.231.460.670.09
Change in Unearned Revenue
-----84.65-10.51
Change in Other Net Operating Assets
11.21-7.560.111.961.9714.43
Operating Cash Flow
-139.25-150.02-162.39-163.69-169.56-126.25
Operating Cash Flow Growth
------

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-0.72-0.78-0.46-2.69-24.28-65.5
Sale of Property, Plant & Equipment
0.030.29----
Cash Acquisitions
-41.2-41.2-31.35---
Investment in Securities
97.195.79154.23186.7312.74-56.07
Investing Cash Flow
55.2254.1122.42184.05-11.54-121.57

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Issuance of Common Stock
52.5150.411.42.211.1401.24
Repurchase of Common Stock
-0-0-0.08-0.46-0.46-
Financing Cash Flow
52.5150.411.331.7410.64401.24

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Cash Flow
-31.52-45.52-38.6422.1-170.46153.42

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-139.97-150.8-162.86-166.38-193.83-191.75
Free Cash Flow Growth
------
Free Cash Flow Margin
-933100.00%-418900.00%-266980.33%-127984.62%-228.89%-1800.50%
Free Cash Flow Per Share
-6.21-8.82-12.46-13.26-15.69-28.22
Levered Free Cash Flow
-65.9-81.47-67.56-90.36-53.9-129.82
Unlevered Free Cash Flow
-65.9-81.47-67.56-90.36-53.9-129.82

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Change in Working Capital
12.6-9.89-3.123.42-82.024.01
SEC Filings: 10-K · 10-Q